Independently minded Ipsen

Rather than put itself up for sale like other European specialty pharma plays, Ipsen Group is taking a different tack. Having raised E171 million ($203 million) in a December IPO, the company is planning to spend the money acquiring projects and reinforcing its U.S. presence.

For years, Ipsen (Euronext:IPN, Paris, France) has followed the path of many family-owned, mid-sized pharma companies in Europe: innovation was limited to improving existing treatments, with a focus on primary care products...